USPTO serial 75094769
ZEONEX
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- BRODIE, DWAYNE P.
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ZEONEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Belinda I. Berman
BELINDA I BERMAN WARNER-LAMBERT COMPANY201 TABOR RDMORRIS PLAINS, NJ 07950UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for use in the treatment of cardiovascular disorders and cholesterol reduction | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 15, 1997 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Jan 16, 1997 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 17, 1996 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 15, 1996 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 18, 1996 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 17, 1996 | CNEA | EXAMINER'S AMENDMENT MAILED | — |
| Sep 12, 1996 | DOCK | ASSIGNED TO EXAMINER | — |